Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease

British Journal of Pharmacology

Volumn 174, Issue 24, 2017, Pages 4716-4724

  Toledo, Enrique M ^a   Gyllborg, Daniel ^a   Arenas, Ernest ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; BETA CATENIN; CT 99021; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; POLO LIKE KINASE 1; WNT3A PROTEIN;

BRAIN DEVELOPMENT; CELL DIFFERENTIATION; CELL TRANSPORT; DOPAMINERGIC SYSTEM; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGICAL PROCEDURES; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SINGLE CELL ANALYSIS; STEM CELL TRANSPLANTATION; TRANSCRIPTION REGULATION; VENTRAL MESENCEPHALON; WNT SIGNALING; ANIMAL; METABOLISM;

ANIMALS; HUMANS; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; WNT SIGNALING PATHWAY;

EID: 85022340007     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13871     Document Type: Review

References (66)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
2. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
3. Andersson ER, Prakash N, Cajanek L, Minina E, Bryja V, Bryjova L et al. (2008). Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. PLoS One 3: e3517.
4. Andersson ER, Saltó C, Villaescusa JC, Cajanek L, Yang S, Bryjova L et al. (2013). Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc Natl Acad Sci U S A 110: E602–E610.
5. Arenas E (2014). Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson’s disease. J Mol Cell Biol 6: 42–53.
6. Arenas E, Denham M, Villaescusa JC (2015). How to make a midbrain dopaminergic neuron. Development 142: 1918–1936.
7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297–315.
8. Barker RA, Barrett J, Mason SL, Björklund A (2013). Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol 12: 84–91.
9. Barker RA, Drouin-Ouellet J, Parmar M (2015a). Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol 11: 492–503.
10. Barker RA, Studer L, Cattaneo E, Takahashi J (2015b). G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease. Npj Park Dis 1: 15017.
11. Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW et al. (2002). Regulation of Wnt signaling during adipogenesis. J Biol Chem 277: 30998–31004.
12. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J (2008). Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121: 737–746.
13. Cajanek L, Adlerz L, Bryja V, Arenas E (2010). WNT unrelated activities in commercially available preparations of recombinant WNT3a. J Cell Biochem 111: 1077–1079.
14. Chen Y, Xiong M, Dong Y, Haberman A, Cao J, Liu H et al. (2016). Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson’s disease. Cell Stem Cell 18: 817–826.
15. Clevers H, Nusse R (2012). Wnt/β-catenin signaling and disease. Cell 149: 1192–1205.
16. Das DS, Wadhwa N, Kunj N, Sarda K, Pradhan BS, Majumdar SS (2013). Dickkopf homolog 3 (DKK3) plays a crucial role upstream of WNT/β-CATENIN signaling for Sertoli cell mediated regulation of spermatogenesis. PLoS One 8: e63603.
17. Denham M, Bye C, Leung J, Conley BJ, Thompson LH, Dottori M (2012). Glycogen synthase kinase 3β and activin/nodal inhibition in human embryonic stem cells induces a pre-neuroepithelial state that is required for specification to a floor plate cell lineage. Stem Cells 30: 2400–2411.
18. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR (2007). Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/betacatenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 12: 957–971.
19. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y et al. (2014). Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2: 337–350.
20. Fahn S (2003). Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991: 1–14.
21. Fernando C, Kele J, Bye C, Niclis JC, Alsanie W, Blakely BD et al. (2014). Diverse roles for Wnt7a in ventral midbrain neurogenesis and dopaminergic axon morphogenesis. Stem Cells Dev 23: 1991–2003.
22. Fukusumi Y, Meier F, Gotz S, Matheus F, Irmler M, Beckervordersandforth R et al. (2015). Dickkopf 3 promotes the differentiation of a rostrolateral midbrain dopaminergic neuronal subset in vivo and from pluripotent stem cells in vitro in the mouse. J Neurosci 35: 13385–13401.
23. Gao B (2012). Wnt regulation of planar cell polarity (PCP). Curr Top Dev Biol 101: 263–295.
24. Giovannantonio LGD, Salvio MD, Acampora D, Prakash N, Wurst W, Simeone A (2013). Otx2 selectively controls the neurogenesis of specific neuronal subtypes of the ventral tegmental area and compensates En1-dependent neuronal loss and MPTP vulnerability. Dev Biol 373: 176–183.
25. Gray RS, Roszko I, Solnica-Krezel L (2011). Planar cell polarity: coordinating morphogenetic cell behaviors with embryonic polarity. Dev Cell 21: 120–133.
26. Grealish S, Diguet E, Kirkeby A, Mattsson B, Heuer A, Bramoulle Y et al. (2014). Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease. Cell Stem Cell 15: 653–665.
27. Harwood AJ (2001). Regulation of GSK-3: a cellular multiprocessor. Cell 105: 821–824.
28. Inestrosa NC, Arenas E (2010). Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11: 77–86.
29. Islam S, Kjällquist U, Moliner A, Zajac P, Fan J-B, Lönnerberg P et al. (2012). Highly multiplexed and strand-specific single-cell RNA 50 end sequencing. Nat Protoc 7: 813–828.
30. Islam S, Kjällquist U, Moliner A, Zajac P, Fan JB, Lönnerberg P et al. (2011). Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res 21: 1160–1167.
31. Islam S, Zeisel A, Joost S, Manno GL, Zajac P, Kasper M et al. (2014). Quantitative single-cell RNA-seq with unique molecular identifiers. Nat Methods 11: 163–166.
32. Janda CY, Dang LT, You C, Chang J, de Lau W, Zhong ZA et al. (2017). SurrogateWnt agonists that phenocopy canonicalWnt and β-catenin signalling. Nature: 1–19.
33. Jenei V, Sherwood V, Howlin J, Linnskog R, Säfholm A, Axelsson L et al. (2009). A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A 106: 19473–19478.
34. Kawano Y, Kypta R (2003). Secreted antagonists of theWnt signalling pathway. J Cell Sci 116: 2627–2634.
35. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M et al. (2014). Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71: 83–87.
36. Kele J, Andersson ER, Villaescusa JC, Cajanek L, Parish CL, Bonilla S et al. (2012). SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells. Stem Cells 30: 865–875.
37. Kikuchi A, Yamamoto H, Sato A, Matsumoto S (2011). New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol 291: 21–71.
38. Kim W-Y, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR et al. (2009). GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 12: 1390–1397.
39. Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M et al. (2012). Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep 1: 703–714.
40. Kirkeby A, Nolbrant S, Tiklova K, Heuer A, Kee N, Cardoso T et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell 20: 135–148.
41. Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, Linnarsson S et al. (2011). Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods 9: 72–74.
42. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, Xie Z et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480: 547–551.
43. La Manno G, Gyllborg D, Codeluppi S, Nishimura K, Salto C, Zeisel A et al. (2016). Molecular diversity of midbrain development in mouse, human, and stem cells. Cell 167: 566–580. e19.
44. Li W, Englund E, Widner H, Mattsson B, vanWesten D, Lätt J et al. (2016). Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A 113: 6544–6549.
45. Martinez S, Crossley PH, Cobos I, Rubenstein JL, Martin GR (1999). FGF8 induces formation of an ectopic isthmic organizer and isthmocerebellar development via a repressive effect on Otx2 expression. Development 126: 1189–1200.
46. McMahon AP, Bradley A (1990). The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 62: 1073–1085.
47. Nakamura REI, Hunter DD, Yi H, Brunken WJ, Hackam AS (2007). Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol 8: 52.
48. Niehrs C (2006). Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469–7481.
49. Niehrs C (2012). The complex world ofWNT receptor signalling. Nat Rev Mol Cell Biol 13: 767–779.
50. Panman L, Papathanou M, Laguna A, Oosterveen T, Volakakis N, Acampora D et al. (2014). Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons. Cell Rep 8: 1018–1025.
51. Park A, Stacy M (2009). Non-motor symptoms in Parkinson’s disease. J Neurol 256 (Suppl): 293–298.
52. Patel P, Woodgett JR (2017). Glycogen synthase kinase 3: a kinase for all pathways? Curr Top Dev Biol 123: 277–302.
53. Prakash N, Brodski C, Naserke T, Puelles E, Gogoi R, Hall A et al. (2006). A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 133: 89–98.
54. Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish CL, Foldi C et al. (2013). Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiol Dis 49: 118–127.
55. Säfholm A, Leandersson K, Dejmek J, Nielsen CK, Villoutreix BO, Andersson T (2006). A formylated hexapeptide ligand mimics the ability ofWnt-5a to impair migration of human breast epithelial cells. J Biol Chem 281: 2740–2749.
56. Säfholm A, Tuomela J, Rosenkvist J, Dejmek J, Härkönen P, Andersson T (2008). The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 14: 6556–6563.
57. Sousa KM, Carlos Villaescusa J, Cajanek L, Ondr JK, Castelo-Branco G, Hofstra W et al. (2010).Wnt2 regulates progenitor proliferation in the developing ventral midbrain. J Biol Chem 285: 7246–7253.
58. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
59. Steinbeck JA, Choi SJ, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D et al. (2015). Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson’s disease model. Nat Biotechnol 33: 204–209.
60. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I et al. (2010). Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143: 1136–1148.
61. Thomas KR, Capecchi MR (1990). Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 346: 847–850.
62. Valenta T, Hausmann G, Basler K (2012). The many faces and functions of β-catenin. EMBO J 31: 2714–2736.
63. Wagner FF, Bishop JA, Gale JP, Shi X, Walk M, Ketterman J et al. (2016). Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chem Biol 11: 1952–1963.
64. Willert K, Nusse R (2012). Wnt proteins. Cold Spring Harb Perspect Biol 4: 1–13.
65. Xi J, Liu Y, Liu H, Chen H, Emborg ME, Zhang S-C (2012). Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 30: 1655–1663.
66. Xiang T, Li L, Yin X, Zhong L, Peng W, Qiu Z et al. (2013). Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells. J Cell Mol Med 17: 1236–1246.